title: [Observation on the therapeutic effect of Lamivudin on chronic hepatitis B].
abstract: OBJECTIVE
  To observe the therapeutic effect of Lamivudine on controlling hepatitis B virus DNA replication.
  
  
  METHODS
  The liver disease patients were divided into two groups, the treated group (n=64) was given Lamivudine 100 mg once a day for one year and was additionally given liver protection drugs according to their liver function, while the control group (n=30) was given common liver protection drugs. The blood routine test, liver function and the viral markers were detected at defined times.
  
  
  RESULTS
  The results showed that after one year treatment of chronic hepatitis B with Lamivudine, the recovery rate of ALT was 90.7%, the negative conversion rate of HBV DNA was 73.1% showing a significant difference as compared with the control group (P<0.05). The negative seroconversion rate of HBeAg was 50%, HBeAg/anti HBe changing rate was 38.2%, that had no significant different as compared with the control group (P<0.05). The percentage for disease relapse and second elevation of ALT was 3.1% in therapeutic group that was significantly different from that of the control group (P<0.05). Two cases with severe hepatitis in the treated group were all alive.
  
  
  CONCLUSIONS
  Lamivudine could effectively control HBV DNA replication, making ALT normal, it also could decrease the relapse rate of chronic hepatitis B and raise the survival rate of the patients with liver disease.
authors.affiliation: The Fifth Affiliated Hospital of Guangxi Medical College, Liuzhou 545001, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Wen
authors.forename: Xuemei
authors.initials: X
authors.lastname: Li
authors.forename: Houyu
authors.initials: H
authors.lastname: Xie
authors.forename: Nian
authors.initials: N
authors.lastname: Chen
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Zeng
authors.forename: Haiyun
authors.initials: H
authors.lastname: Ru
authors.forename: Xaioping
authors.initials: X
authors.lastname: Cui
authors.forename: Zhongmin
authors.initials: Z
authors.lastname: Tang
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D019259:Lamivudine